Home > For Consumers > Interventions for non‐oliguric...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Interventions for non‐oliguric hyperkalaemia in preterm neonates

This version published: 2012; Review content assessed as up-to-date: June 09, 2011.

Plain language summary

Elevated levels of potassium (an important salt for normal body functions) are common in infants born very preterm or with birth weight less than 1500 g. High potassium levels in the blood may lead to irregular or rapid heart rate that may result in bleedings in the brain and/or sudden death. The objective of this review was to determine the effectiveness and safety of interventions for this serious condition. Two studies enrolling 52 infants that assessed the use of a combination of insulin and sugar to reduce the blood levels of potassium were identified. This combination reduced the duration of high blood levels of potassium and the risk for bleeds in the brains of the infants. One study that enrolled 19 patients reported on the use of albuterol (a medication that helps to move potassium from the blood to the body cells). Albuterol lowered the blood levels of potassium both at four and at eight hours after the treatment had started. Because of the few infants enrolled in the studies to date, no firm recommendations for the treatment of too high blood levels of potassium in neonates can be made. Further research is needed.

Abstract

Background: Non‐oliguric hyperkalaemia of the newborn is defined as a plasma potassium level > 6.5 mmol/L in the absence of acute renal failure. Hyperkalaemia is a common complication in the first 48 hours of life in very low birth weight (VLBW) (birth weight < 1500 g) and/or very preterm newborns (< 32 weeks gestational age).

Objectives: To determine the effectiveness and safety of interventions for non‐oliguric hyperkalaemia [for the purpose of this review defined as serum potassium > 6.0 mmol/L (the clinical setting in which interventions would likely be introduced prior to reaching a grossly abnormal level) and urine output > 0.5 ml/kg/hour] in preterm or VLBW infants during their first 72 hours of life.

Search methods: The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2006) was searched to identify relevant randomised and quasi‐randomised controlled trials. The following data bases were searched in June 2006; MEDLINE from 1966, EMBASE from 1980, CINAHL from 1982. Search updated in June 2011.

Selection criteria: Randomised or quasi‐randomised controlled trials conducted in preterm and/or VLBW neonates with a diagnosis of non‐oliguric hyperkalaemia. Interventions included were those aimed at redistributing serum potassium (sodium bicarbonate or insulin and glucose) or increasing the elimination of potassium from the body [diuretics (any type) or ion exchange resins (any type), or exchange transfusion, or peritoneal dialysis, or salbutamol, or albuterol] or counteracting potential arrhythmias from hyperkalaemia (calcium) versus placebo or no intervention; or comparing any two of these interventions. Primary outcome measure was 'All cause mortality during initial hospital stay'. Secondary outcomes included common adverse outcomes seen in preterm infants.

Data collection and analysis: We used the standard review methods of the Cochrane Neonatal Review Group. Two authors assessed all studies identified as potentially relevant by the literature search for inclusion in the review. Statistical methods included relative risk (RR), risk difference (RD), number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH) for dichotomous and weighted mean difference (WMD) for continuous outcomes reported with 95% confidence intervals (CI). We used a fixed effect model for meta‐analysis. Heterogeneity was assessed using the I squared (I2 ) statistic.

Main results: Three randomised trials, enrolling 74 preterm infants (outcome data available on 71 infants) evaluated interventions for hyperkalaemia. Urine output was ascertained in only one study (Hu 1999). In none of the trials could we ascertain that allocation to the comparison groups was concealed. The sample sizes of the three trials were very small with 12 (Malone 1991), 19 (Singh 2002) and 40 infants enrolled (Hu 1999). The intervention and the outcome assessments could not be blinded to the clinical staff in two trials (Malone 1991; Hu 1999).

One study (Malone 1991), glucose and insulin, compared to cation‐exchange resin, caused a reduction in all cause mortality that was of borderline statistical significance: RR 0.18 (95% CI 0.03 to 1.15); RD ‐0.66 (95% CI ‐1.09 to ‐0.22); NNTB 2 (95% CI 1 to 5)]. In the study of Hu (Hu 1999), the incidence of intraventricular haemorrhage ≥ grade 2 was significantly reduced [RR 0.30 (95% CI 0.10 to 0.93); RD ‐0.35 (95% CI ‐0.62 to ‐0.08); NNTB 3 (95% CI 2 to 13).

Albuterol inhalation versus saline inhalation changed serum K+ from baseline at four hours [WMD ‐0.69 mmol/L (95% CI ‐0.87 to ‐0.51)] and at eight hours [WMD ‐0.59 mmol/L (95% CI ‐0.78 to ‐0.40)] after initiation of treatment. No differences noted in mortality or other clinical outcomes (Singh 2002).

No serious side effects were noted with either the combination of insulin and glucose or albuterol inhalation. Other interventions listed in our objectives have not been studied to date.

Authors' conclusions: In view of the limited information from small studies of uncertain quality, no firm recommendations for clinical practice can be made. It appears that the combination of insulin and glucose is preferred over treatment with rectal cation‐resin for hyperkalaemia in preterm infants. Both the combination of insulin and glucose and albuterol inhalation deserve further study. The two interventions could possibly be tested against each other. The effectiveness of other potentially effective interventions for non‐oliguric hyperkalaemia (diuretics, exchange transfusion, peritoneal dialysis and calcium) have not been tested in randomised controlled trials.

Editorial Group: Cochrane Neonatal Group.

Publication status: New search for studies and content updated (no change to conclusions).

Citation: Vemgal P, Ohlsson A. Interventions for non‐oliguric hyperkalaemia in preterm neonates. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD005257. DOI: 10.1002/14651858.CD005257.pub3. Link to Cochrane Library. [PubMed: 22592703]

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 22592703

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...